| Literature DB >> 27180068 |
Lynn Marie Trotti1,2, Elias G Karroum3.
Abstract
In patients with neurodegenerative diseases, sleep disorders are common; they impair the quality of life for patients and caregivers and are associated with poorer clinical outcomes. Melatonin has circadian, hypnotic, and free radical-scavenging effects, and preclinical data suggest benefits of melatonin on neurodegeneration. However, randomized, controlled trials of melatonin in patients with neurodegenerative diseases have not shown strong effects. Trials in Alzheimer's patients demonstrate a lack of benefit on sleep quantity. Subjective measures of sleep quality are mixed, with possible symptomatic improvements seen only on some measures or at some time points. Benefits on cognition have not been observed across several studies. In Parkinson's patients, there may be minimal benefit on objective sleep measures, but a suggestion of subjective benefit in few, small studies. Effective treatments for the sleep disorders associated with neurodegenerative diseases are urgently needed, but current data are insufficient to establish melatonin as such a treatment.Entities:
Keywords: Alzheimer’s disease; Circadian rhythm; Insomnia; Melatonin; Neurodegenerative disease; Parkinson’s disease; REM sleep behavior disorder
Mesh：
Substances：
Year: 2016 PMID： 27180068 DOI： 10.1007/s11910-016-0664-3
Source DB: PubMed Journal: Curr Neurol Neurosci Rep ISSN： 1528-4042 Impact factor: 5.081